J. Pediatr. (Rio J.) vol.80 número6 en v80n6a15
Texto
Imagem
Documentos relacionados
We describe the clinical manifestations and physical capacity defi cits of patients with juvenile idiopathic arthritis (JIA), juvenile dermatomyositis (JDM), juvenile systemic lupus
sustained clinical improvement in a patient with systemic onset juvenile idiopathic arthritis refractory to TNF alpha antagonists. Rituximab: mechanism
Macrophage activation syndrome (MAS) is a severe complication of rheumatic diseases that occurs much more frequently in patients with systemic juvenile idio- pathic arthritis
Erratum to “Effects of the use of growth hormone in children, adolescents with juvenile idiopathic arthritis: a systematic review”. (Rev
This table presents the results on the two-stage least squares estimation, for the analysis of the relation between incentive-aligned executive compensation and firm value
Objective: To measure and compare musculoskeletal pain in patients with juvenile fibromyalgia (JFM) and polyarticular juvenile idiopathic arthritis (JIA), and to evaluate and
The serum IL-6 levels in various disease groups were all signi fi cantly higher than the healthy control group (P o 0.05), but the IL-6 concentration showed no signi fi - cant
Objective: To measure and compare musculoskeletal pain in patients with juvenile fibromyalgia (JFM) and polyarticular juvenile idiopathic arthritis (JIA), and to evaluate and